Company intelligence / Profile preview

Utopic Pharms

Monmouth Junction, New Jersey, USA

Ownership: Private
Development stage: Other

Overview

Utopic Pharms is a clinical-stage biopharmaceutical company focused on developing novel small molecule drugs for oncology and autoimmune diseases. The company's lead program, UP-1001, is a dual-functional inhibitor targeting PI3K and BRD4, which is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors and lymphomas. By targeting multiple pathways simultaneously, Utopic Pharms aims to address drug resistance and improve patient outcomes in hard-to-treat cancers. The company is headquartered in New Jersey and maintains research and development operations to expand its pipeline of multi-targeted therapeutic candidates.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Utopic Pharms.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Utopic Pharms.

Explore the full profile